Overview
- Reviews the brief history and rapid rise of senotherapeutics and senolytics in modern medicine
- Describes additional avenues of research into senescence SASP and tissue engineering
- Will benefit a broad readership of advanced educators, researchers, graduate students and practitioners
Part of the book series: Healthy Ageing and Longevity (HAL, volume 11)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (11 chapters)
-
Front Matter
-
Origins and Development of Senotherapies
-
Front Matter
-
-
The Impact of Senotherapies: From Regeneration to Aging
-
Front Matter
-
-
Understanding and Targeting the Senescent Surfaceome
-
Front Matter
-
-
Novel Senescence-Associated Markers and Targets
-
Front Matter
-
Keywords
About this book
This book offers comprehensive information on the new and rapidly evolving science of identifying and targeting senescent cells, and on the exciting prospect of new diagnostic and therapeutic opportunities for stopping, and even reversing, the progression of disease and the deterioration of the human body due to ageing.
According to recent United Nations data, by 2050 one in six people worldwide will be older than age 65, with peaks rising to one in four people in Europe and North America. Remarkably, the number of persons aged 80 years or older is expected to triple, from 143 million in 2019 to 426 million in 2050.
First documented in the 1960s, the concept of cellular senescence as an underlying cause of ageing has been established in the course of the last decade. Using genetically engineered mouse models, researchers have demonstrated that the selective elimination of senescent cells can block and even reverse a number of age-related dysfunctions and pathologies, promoting both better health and longer life in the elderly. These include cardiovascular diseases; neurological disorders; type 1 and type 2 diabetes; inflammatory diseases; fibrosis; geriatric syndromes; chronic diseases resulting in organ dysfunction; the integrity of the musculoskeletal system; and cancer. Some senolytic agents have already progressed into trials. These include UBX0101 for the treatment of osteoarthritis (now in phase II), a cocktail of dasatinib and quercetin for the management of idiopathic pulmonary fibrosis and chronic kidney disease, and ABT-263 in combination with senescence-inducing chemotherapies for the treatment of advanced solid tumours.
In addition, the book discusses pathways to early phase clinical trials and translational approaches in medicine and ageing, highlighting new opportunities as well as current limitations, challenges and alternatives. Given its scope, it will benefit a broad audience of advanced educators, researchers, graduate students and practitioners.
Editors and Affiliations
Bibliographic Information
Book Title: Senolytics in Disease, Ageing and Longevity
Editors: Daniel Muñoz-Espin, Marco Demaria
Series Title: Healthy Ageing and Longevity
DOI: https://doi.org/10.1007/978-3-030-44903-2
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2020
Hardcover ISBN: 978-3-030-44902-5Published: 28 April 2020
Softcover ISBN: 978-3-030-44905-6Published: 29 April 2021
eBook ISBN: 978-3-030-44903-2Published: 27 April 2020
Series ISSN: 2199-9007
Series E-ISSN: 2199-9015
Edition Number: 1
Number of Pages: X, 222
Number of Illustrations: 5 b/w illustrations, 16 illustrations in colour
Topics: Biogerontology, Regenerative Medicine/Tissue Engineering, Animal Models, Molecular Medicine